These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 34171106)
1. Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use. Cunill R; Castells X; González-Pinto A; Arrojo M; Bernardo M; Sáiz PA; Flórez G; Torrens M; Tirado-Muñoz J; Fonseca F; Arranz B; Garriga M; Goikolea JM; Zorrilla I; Becoña E; López A; San L Adicciones; 2022 Apr; 34(2):168-178. PubMed ID: 34171106 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Pérez de los Cobos J; Siñol N; Pérez V; Trujols J Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449 [TBL] [Abstract][Full Text] [Related]
3. [Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice]. Adorjan K; Karch S; Martin G; Plörer D; Winter C; Hantschk I; Koller G; Erbas B; Pogarell O MMW Fortschr Med; 2019 Jul; 161(Suppl 5):7-12. PubMed ID: 31313269 [TBL] [Abstract][Full Text] [Related]
4. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders. Simon N; Rolland B; Karila L Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112 [TBL] [Abstract][Full Text] [Related]
5. Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. Jordan CJ; Harvey RC; Baskin BB; Dwoskin LP; Kantak KM Drug Alcohol Depend; 2014 Jul; 140():25-32. PubMed ID: 24811203 [TBL] [Abstract][Full Text] [Related]
6. Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder. Torrens M; Tirado-Muñoz J; Fonseca F; Farré M; González-Pinto A; Arrojo M; Bernardo M; Arranz B; Garriga M; Sáiz PA; Flórez G; Goikolea JM; Zorrilla I; Cunill R; Castells X; Becoña E; López A; San L Adicciones; 2022 Apr; 34(2):128-141. PubMed ID: 33768269 [TBL] [Abstract][Full Text] [Related]
7. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Perugi G; Vannucchi G Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896 [TBL] [Abstract][Full Text] [Related]
8. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Klassen LJ; Bilkey TS; Katzman MA; Chokka P Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy]. Mulas F; Roca P; Ros-Cervera G; Gandía-Benetó R; Ortiz-Sánchez P Rev Neurol; 2014 Feb; 58 Suppl 1():S43-9. PubMed ID: 25252667 [TBL] [Abstract][Full Text] [Related]
10. Adult Attention-Deficit Hyperactivity Disorder/Substance Use Disorder Dual Disorder Patients: A Dual Disorder Unit Point of View. Maremmani I; Spera V; Maiello M; Maremmani AGI; Perugi G Curr Top Behav Neurosci; 2022; 57():179-198. PubMed ID: 35507285 [TBL] [Abstract][Full Text] [Related]
11. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Kollins SH Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709 [TBL] [Abstract][Full Text] [Related]
12. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025 [TBL] [Abstract][Full Text] [Related]
13. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications. Schubiner H CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847 [TBL] [Abstract][Full Text] [Related]
14. Remarkable Reduction of Cocaine Use in Dual Disorder (Adult Attention Deficit Hyperactive Disorder/Cocaine Use Disorder) Patients Treated with Medications for ADHD. Manni C; Cipollone G; Pallucchini A; Maremmani AGI; Perugi G; Maremmani I Int J Environ Res Public Health; 2019 Oct; 16(20):. PubMed ID: 31618876 [No Abstract] [Full Text] [Related]
15. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. Stuhec M; Munda B; Svab V; Locatelli I J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457 [TBL] [Abstract][Full Text] [Related]
17. Concomitant Drug Use among Opioid-Dependent Patients with and without Attention Deficit Hyperactivity Disorder: Does Methylphenidate Merit a Trial? Tschudi L; Fischer SKM; Perlov E; Baumgartner MR; Soyka M; Müller TJ; Seifritz E; Mutschler J Eur Addict Res; 2023; 29(5):305-312. PubMed ID: 37517394 [TBL] [Abstract][Full Text] [Related]
18. Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis. Moukhtarian TR; Cooper RE; Vassos E; Moran P; Asherson P Eur Psychiatry; 2017 Jul; 44():198-207. PubMed ID: 28646732 [TBL] [Abstract][Full Text] [Related]
19. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Shang CY; Pan YL; Lin HY; Huang LW; Gau SS J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447 [TBL] [Abstract][Full Text] [Related]
20. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]